Patients living with primary immunodeficiency (PI) disorders face prolonged or severe infections that pose significant challenges to daily life. While infectious PI phenotypes have garnered the most visibility, this focus has left noninfectious variants underrecognized and delayed in diagnosis, leading …
Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While …
Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While …
Primary Immunodeficiency (PI) disorders are a group of more than 180 inherited disorders, of the approximately 550 inborn errors of immunity (IEIs), that predispose affected patients to a variety of bacterial, viral, and fungal infections. Infections may be more prolonged …
With recent approvals of semaglutide and resmetirom, the treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) has entered a new era. In this final webisode of a 4-part CME Outfitters series, expert faculty look ahead to the next wave of therapeutic …
Complicated urinary tract infections (cUTIs) represent an important and growing challenge in clinical practice, affecting individual patients’ health and quality of life while exerting a substantial burden on the healthcare system. Despite being common, these infections are underrecognized. The July …
